All news from Anaesthesiology

Skin Disease Affects Based On Skin Conditions

Although skin disease can affect anyone, it may not affect everyone in the same way and this is especially true for patients with skin of color. Skin conditions are color blind, occurring in patients of every skin tone, but certain conditions can affect patients with skin of color more frequently and more severely.

Skin Treatments

Moreover, certain dermatologic treatments may cause problems in this population if those treatments aren't performed properly by a qualified, experienced physician like a board-certified dermatologist.

Long-term Effects Of Microgravity Changes The Physiology Of Human Brain

A study reports that the prolonged effects of microgravity raise doubts about the health of astronauts heading to Mars. Artificial gravity has been a highly useful concept for film directors wishing to depict life in space without the need to simulate zero gravity; it may yet prove a necessary technology for humans to venture to Mars and beyond, to overcome what appears an unavoidable neurological barrier to humans spending long periods in the weightless environment of a spaceship.

One blindingly apparent symptom to emerge from astronauts (and cosmonauts) spending prolonged periods in space is damage to their eyesight. Dubbed visual impairment intracranial pressure (VIIP) syndrome, the condition has been thought to be caused by changes in fluid pressure within the skull.

Contact Sports Associated with Neural Diseases, Findings

There is mounting evidence that repetitive head impacts from contact sports and other exposures are associated with the neurodegenerative disease chronic traumatic encephalopathy (CTE) and dementia. A new study suggests that contact sports athletes may also be at increased risk for Lewy Body Disease, which can cause Parkinson's disease, a brain disorder that leads to problems with movement and thinking.

New Treatment For A Severe Lung Disease

Scientists at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago took a major step toward developing a new treatment for pulmonary arterial hypertension (PAH), a severe lung disease with a five-year survival rate of 50%.

They identified a drug with a positive safety profile that inhibits a gene called HIF-2α, which they discovered earlier promotes the progressive thickening of the lung artery walls, a key feature of PAH called "vascular remodeling," which leads to right-sided heart failure, the main cause of death in PAH patients.

Recently, they demonstrated in three clinically-relevant animal models that inhibiting HIF-2α with a compound results in reversal of established PAH, suppression of vascular remodeling and right heart failure, and increased survival. The study was published in the American Journal of Respiratory Critical Care Medicine.